A Phase 1 Study of Milademetan in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia that are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
The study has 2 parts: Part 1 and Part 2. This consent is for Part 1 only. The goal of Part 1 of this clinical research study is to test different doses of the 2 study drugs (milademetan and quizartinib) at different dosing schedules. The safety of the study drugs will also be studied.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: DS-3032b, Quizartinib
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Daiichi Sankyo, Inc.
IRB Review and Approval Date: 09/05/2018
Recruitment Status: Open
Projected Accrual: 116
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: